Trial Profile

Clinical Trial to Evaluate the Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogenic cellular therapy Creative Medical Technology (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions
Acronyms CREATE-1
Sponsors Creative Medical Technology Holdings

Most Recent Events

07 Apr 2023 Status changed from not yet recruiting to recruiting.
07 Mar 2023 According to Creative Medical Technology Holdings, the company expects to commence this study during the first quarter of 2023.
07 Mar 2023 According to Creative Medical Technology Holdings media release, the company has engaged with the Syneos Health as the contract research organization (CRO) for this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com